Investigational Drug Information for BAY1834845
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug BAY1834845?
BAY1834845 is an investigational drug.
There have been 5 clinical trials for BAY1834845.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 21st 2022.
The most common disease conditions in clinical trials are Pelvic Infection, Dermatitis, and Psoriasis. The leading clinical trial sponsors are Bayer and [disabled in preview].
There are three US patents protecting this investigational drug and one hundred and twenty international patents.
Summary for BAY1834845
| US Patents | 3 |
| International Patents | 120 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2022-12-21) |
| Vendors | 12 |
Recent Clinical Trials for BAY1834845
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis | Bayer | Phase 2 |
| A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants | Bayer | Phase 1 |
| A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis | Bayer | Phase 1 |
Clinical Trial Summary for BAY1834845
Top disease conditions for BAY1834845
Top clinical trial sponsors for BAY1834845
US Patents for BAY1834845
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BAY1834845 | See Plans and Pricing | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | See Plans and Pricing |
| BAY1834845 | See Plans and Pricing | Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6- -(trifluoromethyl)pyridine-2-carboxamide | Bayer Pharma Aktiengesellschaft (Berlin, DE) | See Plans and Pricing |
| BAY1834845 | See Plans and Pricing | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | Bayer Pharma Aktiengesellschaft (Berlin, DE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BAY1834845
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BAY1834845 | Argentina | AR102827 | 2034-11-26 | See Plans and Pricing |
| BAY1834845 | Australia | AU2015352603 | 2034-11-26 | See Plans and Pricing |
| BAY1834845 | Australia | AU2020200979 | 2034-11-26 | See Plans and Pricing |
| BAY1834845 | Brazil | BR112017011005 | 2034-11-26 | See Plans and Pricing |
| BAY1834845 | Canada | CA2968614 | 2034-11-26 | See Plans and Pricing |
| BAY1834845 | Chile | CL2017001364 | 2034-11-26 | See Plans and Pricing |
| BAY1834845 | China | CN107406416 | 2034-11-26 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
